Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 and Randomized Phase 2 Trial of Pidnarulex (CX-5461) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer

NCT07147231 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07147231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07147231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 and Randomized Phase 2 Trial of Pidnarulex (CX-5461) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 10, 2026
Completion date
September 30, 2027
Enrollment
86 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal adenocarcinoma, refractory colorectal adenocarcinoma, stage iii colorectal cancer ajcc v8, stage iv colorectal cancer ajcc v8, unresectable colorectal adenocarcinoma